Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 783

1.

Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.

Dajani EZ, Islam K.

J Physiol Pharmacol. 2008 Aug;59 Suppl 2:117-33. Review.

2.

Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.

Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.

J Med Assoc Thai. 2009 Dec;92 Suppl 6:S19-26.

PMID:
20128070
3.

Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.

Scheiman JM, Hindley CE.

Clin Ther. 2010 Apr;32(4):667-77. doi: 10.1016/j.clinthera.2010.04.009. Review.

PMID:
20435236
4.

An evidence-based evaluation of the gastrointestinal safety of coxibs.

Bombardier C.

Am J Cardiol. 2002 Mar 21;89(6A):3D-9D. Review.

PMID:
11909555
5.

Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.

Joshi GP, Gertler R, Fricker R.

Anesth Analg. 2007 Dec;105(6):1793-804, table of contents. Review.

PMID:
18042885
6.

Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.

Lehmann FS, Beglinger C.

Curr Top Med Chem. 2005;5(5):449-64. Review.

PMID:
15974940
8.

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.

Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.

Arthritis Rheum. 2006 May;54(5):1378-89.

9.

The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.

van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.

Ann Rheum Dis. 2009 May;68(5):668-73. doi: 10.1136/ard.2007.087254. Epub 2008 May 21.

PMID:
18495734
10.

Anti-inflammatory drugs in the 21st century.

Rainsford KD.

Subcell Biochem. 2007;42:3-27. Review.

PMID:
17612044
11.

Cardiovascular complications of non-steroidal anti-inflammatory drugs.

Fosslien E.

Ann Clin Lab Sci. 2005 Autumn;35(4):347-85. Review.

PMID:
16254252
12.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
13.

[Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].

van den Bemt BJ, Benraad HB, Rasker JJ.

Ned Tijdschr Geneeskd. 2007 May 12;151(19):1062-7. Review. Dutch.

PMID:
17552414
14.

Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.

Chaiamnuay S, Allison JJ, Curtis JR.

Am J Health Syst Pharm. 2006 Oct 1;63(19):1837-51. Review.

PMID:
16990630
16.

The use of NSAIDs in rheumatic disorders 2005: a global perspective.

Kean WF, Buchanan WW.

Inflammopharmacology. 2005;13(4):343-70. Review.

PMID:
16354389
17.

Cardiovascular issues of COX-2 inhibitors and NSAIDs.

Wong M, Chowienczyk P, Kirkham B.

Aust Fam Physician. 2005 Nov;34(11):945-8. Review.

18.

Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.

Circulation. 2006 Jun 27;113(25):2906-13. Epub 2006 Jun 19.

19.

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.

Antoniou K, Malamas M, Drosos AA.

Expert Opin Pharmacother. 2007 Aug;8(11):1719-32. Review.

PMID:
17685888
20.

[Can COX-2 selective inhibitor prevent NSAIDs-related GI toxicity?].

Konishi H, Yoshikawa T.

Nihon Rinsho. 2011 Jun;69(6):1110-5. Japanese.

PMID:
21688637

Supplemental Content

Support Center